Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3428]
News [7862]
Articles [63]
Editorials [9]
Conferences [212]
elearning [49]
Preliminary results from KEYNOTE-055: pembrolizumab in HNSCC
Dr Joshua Bauml - University of Pennsylvania, Philadelphia, USA
Preliminary results from KEYNOTE-055: pembrolizumab in HNSCC ( Dr Joshua Bauml - University of Pennsylvania, Philadelphia, USA )
6 Jun 2016
Targetting PD-L1 with avelumab in metastatic Merkel cell carcinoma
Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, USA
Targetting PD-L1 with avelumab in metastatic Merkel cell carcinoma ( Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, USA )
6 Jun 2016
Ten years of letrozole improves survival and quality of life in early-diagnosed...
Dr Julie Lemieux - Hôpital du Saint-Sacrement, Québec, Canada
Ten years of letrozole improves survival and quality of life in early-diagnosed breast cancer. ( Dr Julie Lemieux - Hôpital du Saint-Sacrement, Québec, Canada )
6 Jun 2016
Daratumumab slows progression in refractory multiple myeloma
Prof Palumbo - University of Turin, Turin, Italy
Daratumumab slows progression in refractory multiple myeloma ( Prof Palumbo - University of Turin, Turin, Italy )
6 Jun 2016
Developments in haematological malignancies
Dr Stephen Nimer - University of Miami, Miami, USA
Developments in haematological malignancies ( Dr Stephen Nimer - University of Miami, Miami, USA )
6 Jun 2016
Recent developments in targeted therapies
Dr Stephen Nimer - University of Miami, Miami, USA
Recent developments in targeted therapies ( Dr Stephen Nimer - University of Miami, Miami, USA )
6 Jun 2016
MyPathway guidance of targeted therapy based on molecular profiles
Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA
MyPathway guidance of targeted therapy based on molecular profiles ( Dr John Hainsworth - Sarah Cannon Research Institute, Nashville, USA )
6 Jun 2016
Testing the safety and efficacy of the PD-L1 antibody durvalumab
Dr Christophe Massard - Institut Gustave Roussy, Paris, France
Testing the safety and efficacy of the PD-L1 antibody durvalumab ( Dr Christophe Massard - Institut Gustave Roussy, Paris, France )
6 Jun 2016
Subset of anaplastic glioma patients benefit from adjuvant chemo
Dr Martin van den Bent - Erasmus MC Cancer Center, Rotterdam, The Netherlands
Subset of anaplastic glioma patients benefit from adjuvant chemo ( Dr Martin van den Bent - Erasmus MC Cancer Center, Rotterdam, The Netherlands )
6 Jun 2016
Advanced RET-rearranged NSCLC
Dr Takashi Seto and Dr Kiyotaka Yoh
Advanced RET-rearranged NSCLC ( Dr Takashi Seto and Dr Kiyotaka Yoh )
6 Jun 2016
Update on olaparib in ovarian cancer
Prof Jonathan Ledermann - University College Hospital Medical School, London, UK
Update on olaparib in ovarian cancer ( Prof Jonathan Ledermann - University College Hospital Medical School, London, UK )
6 Jun 2016
CPX-351 improves outcomes for refractory AML
Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center, Tampa, USA
CPX-351 improves outcomes for refractory AML ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center, Tampa, USA )
6 Jun 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation